Company News

02/23/2022

KeViRx, Inc selected as part of BLUE KNIGHT™ collaboration for global health preparedness

Charlottesville, Virginia – KeViRx, Inc. (“KeViRx”) has been selected to join Blue Knight, a joint initiative between Johnson & Johnson Innovation – JLABS and the Biomedical Advanced Research and Development Authority (BARDA), a component of the U.S. Department of Health and Human Services.  Blue Knight is a collaborative program designed to anticipate and respond to

02/22/2022

Chandra Briggman column: Filling the nation’s need for essential medicines

Richmond, VA, (Richmond Times Dispatch) – While many of us have been focused this month on the Olympics and Super Bowl, another competition is underway that could make an enormous impact on our community and nation. The Build Back Better Regional Challenge is a historic grant competition issued by the U.S. Economic Development Administration. BBBRC

02/22/2022

CEE to Host STEM Lyceums Events for Students

McLean, Va. – The Center for Excellence in Education (CEE) announces its spring 2022 schedule of virtual science, technology, engineering, and mathematics (STEM) Lyceums events for high school students. CEE’s STEM Lyceums are free monthly virtual meetings that will engage high school students in discussion and exploration of STEM concepts and unique STEM career pathways, provided

02/16/2022

Children’s National uses HIFU to perform first ever non-invasive brain tumor surgery

Washington, D.C., Children’s National Hospital successfully performed the first-ever high-intensity focused ultrasound (HIFU) surgery on a pediatric patient with neurofibromatosis (NF). This is the youngest patient to undergo HIFU treatment in the world. The advancement of children’s medical devices in the U.S. continues to significantly lag behind adult devices. This is why this milestone marks

02/16/2022

TearSolutions, Inc. Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Lacripep™

CHARLOTTESVILLE, Va., (GLOBE NEWSWIRE) — TearSolutions, Inc. (“the Company”), a privately held developer of a replacement therapy for the treatment of Dry Eye Disease (DED) called Lacripep, today announced that in late 2021 it received official minutes from a Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the development of Lacripep

02/16/2022

ADIAL PHARMACEUTICALS ANNOUNCES CLOSING OF $10 MILLION FINANCING

CHARLOTTESVILLE, Va., (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the closing of its previously announced registered direct offering, whereby a single accredited institutional investor purchased approximately $10 million of

02/16/2022

ZielBio Announces First Patient Dosed in Phase 1/2 Clinical Trial of ZB131, Its Novel Monoclonal Antibody Targeting Cancer Specific Plectin

CHARLOTTESVILLE, Va., /PRNewswire/ — ZielBio, Inc., a clinical stage biotechnology company discovering new treatments for cancer through its innovative ZielFind drug discovery platform, today announced the first patient dosed in its Phase 1/2 clinical trial. The study will evaluate ZB131 in patients with solid tumors who are either non-responsive to or ineligible for the standard

02/16/2022

ATCC Announces Awards from DTRA that Strengthen ATCC’s Antiviral Drug Discovery and Development Portfolio for Global Health and Biodefense

Manassas, VA, ATCC, the world’s premier biological materials management and standards organization, announced that it has been awarded three grants valued at over $5.5 million by the Defense Threat Reduction Agency (DTRA). The work will identify and characterize novel therapeutic approaches to viruses of global health concern. Promising therapeutic candidates will be tested for efficacy with

02/16/2022

ATCC Announces Awards from DTRA that Strengthen ATCC’s Antiviral Drug Discovery and Development Portfolio for Global Health and Biodefense

Manassas, VA, ATCC, the world’s premier biological materials management and standards organization, announced that it has been awarded three grants valued at over $5.5 million by the Defense Threat Reduction Agency (DTRA). The work will identify and characterize novel therapeutic approaches to viruses of global health concern. Promising therapeutic candidates will be tested for efficacy with in

02/11/2022

Vibrent Health Rebrands its Health Research Participant Portal as “Participant Cloud” to Reflect Virtual Research Capabilities, Accessibility and Flexibility

Vibrent Health enhances and rebrands its consumer-facing digital health platform for data collection, recruitment and engagement of health research participants   Fairfax, VA., – Vibrent Health, a digital health technology startup dedicated to powering the future of precision health research, announced a rebranding of their participant-facing digital health research portal and mobile apps, formerly the

01/31/2022

UVA teaming up with Charlottesville pharmaceutical company for new burn treatment

CHARLOTTESVILLE, Va. (WVIR) – The University of Virginia School of Medicine is teaming up with a Charlottesville company to create a new burn treatment. Typically when skin is burned, the area surrounding it is impacted and dead, too. This new treatment is a cream that is put directly on severe wounds. “Our hope is that

01/25/2022

GMU/ICAP Mentorship Program Connects Mentors with Growing Life Science Startups

Baltimore, MD, (BioBuzz) – Developing an ecosystem for life sciences startups takes a lot of energy and support. The Innovation Commercialization Assistance Program (ICAP), a program of George Mason University and the Virginia SBDC, has been laying the groundwork to support these emerging companies and has tapped two new life sciences mentors to provide guidance

01/24/2022

ADIAL PHARMACEUTICALS RECEIVES NOTICE OF ALLOWANCE ON U.S. PATENT FOR THE TREATMENT FOR OPIOID USE DISORDER USING AD04

CHARLOTTESVILLE, Va., (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the U.S. Patent and Trademark Office (USPTO) has mailed a Notice of Allowance for US Patent Application No. 16/784,051, a patent application for the treatment for opioid

01/20/2022

New Report Outlines Best Practices in Bioscience Economic Development Initiatives

The Biotechnology Innovation Organization (BIO), in partnership with the Council of State Bioscience Associations (CSBA), released a new report on bioscience economic development best practices, “Driving the Bioscience Economy Forward During the COVID-19 Pandemic: Best Practices in State and Regional Economic Development Initiatives.” Now in its sixth edition, the report serves as a leading analysis

01/14/2022

Cadence Adds New Class 7 (10,000) Cleanroom in Connecticut

Cadence, Inc., a leading contract manufacturer of medical devices, announced today the completion of a certified International Organization for Standardization (ISO) Class 7 (10,000) cleanroom at its Connecticut manufacturing facility.  The new cleanroom is dedicated to the production of innovative medical device components and subassemblies. “The cleanroom opens the door to new, exciting opportunities for

01/13/2022

Vibrent Health Integrates Electronic Health Records into its Digital Research Platform, Empowering Participants to Share Their Data for Clinical Research

New framework based on HL7 Fast Healthcare Interoperability Resources (FHIR) gives Standards based access to EHR data to accelerate clinical research and digital trials FAIRFAX, Va. — Vibrent Health, a health technology startup powering the future of precision health research, announced the integration of electronic health record (EHR) data into its Digital Health Solutions Platform, a

01/11/2022

Hibiscus BioVentures Partners with the Barbara Ann Karmanos Cancer Institute to Advance Translational Cancer Research

ROCKVILLE, Md.–(BUSINESS WIRE)– Hibiscus BioVentures, a firm committed to building patient-focused companies around transformative technologies, today announced it has entered into a partnership agreement with the Detroit-based Barbara Ann Karmanos Cancer Institute   (Karmanos). This partnership between Hibiscus’ venture studio, Hibiscus BioTechnology, and Karmanos seeks to leverage the combined resources of the two organizations to develop innovative therapeutics for

01/11/2022

Inorganic Ventures Expands With New Enterprise Development Team

Inorganic Ventures, a manufacturer of high-quality analytical inorganic standards for testing in a wide range of industries, today announced the addition of a new Enterprise Development division. Led by Justin Yalung, Chief Operating Officer, the company’s Enterprise Development arm will have overall authority for developing new products and expanding the organization’s portfolio. “The Enterprise Development division

01/10/2022

New Patent for Caretaker Medical

Caretaker Medical has received issuance of a new Patent by the United States Patent and Trademark Office (USPTO) for self-calibrating systems for blood pressure wave form analysis and diagnostics, U.S. Patent No. 11,207,034, further strengthening the Company’s intellectual property position and coverage for the Company’s medical-grade continuous digital blood pressure and vital sign monitoring system.

01/10/2022

Polycarbin Comes out of Stealth, Raising $2M from Ringbolt Capital and VoLo Earth Ventures to Decarbonize the Life Science and Healthcare Sector

SAN FRANCISCO–(BUSINESS WIRE)–Today, Polycarbin, Inc. announced the closing of a $2M seed round with funding from Ringbolt Capital, VoLo Earth Ventures, along with several notable angel investors to scale the only Closed-Loop solution for single-use plastics in the life science and healthcare sector. In the midst of a pandemic that has destabilized the supply chains

01/07/2022

ATCC Announces Award from Leidos Biomedical Research for the Production and Distribution of Next-generation Cancer Models

ATCC, the world’s premier biological materials management and standards organization, today announced that it has been awarded a contract with Leidos Biomedical Research, Inc. (Leidos Biomed), current operator of the Frederick National Laboratory for Cancer Research, for the continued production, characterization and distribution of next-generation cancer models (NGCM). These models will be distributed solely by ATCC as

01/06/2022

SanAir Technologies Laboratory Combines with Centek Laboratories

Expands Lab Testing Capabilities into Volatile Organic Compound (VOC) Air and Soil Gas Analysis RICHMOND, Va., SanAir Technologies Laboratory, Inc. (SanAir) today announced its merger with Syracuse, NY-based Centek Laboratories, LLC (Centek), expanding its testing capabilities into VOCs using summa cannister and/or thermal desorption tubes technology (EPA Method TO-15 and TO-17) and analyzation of samples by GC/MS coupled with

01/04/2022

Fralin Biomedical Research Institute biotech spin-out raises additional $305,000 in investments

Acomhal Research Inc., a cancer research start-up founded by Fralin Biomedical Research Institute at VTC scientists, recently secured $305,000 in funding from the Virginia Tech Carilion Seed Fund, the Virginia Innovation Partnership Corporation, and angel investors. With a wave of new grants and investments, a cancer stem cell research company founded by Fralin Biomedical Research Institute

12/15/2021

VT Corporate Research Center Receives GO Virginia Grant to Expand Lab Facilities and Resources

New collaboration with Johnson & Johnson Innovation announced with the aim to accelerate life science sector growth in the New River and Roanoke Valleys by providing access to expert mentors, programming, and commercialization resources for startup companies The GO Virginia Coalition today approved a grant award to the Virginia Tech Corporate Research Center (VTCRC) to fund the expansion